Replies to post #42147 on Ocata Therapeutics Inc fka OCAT

[ddls]

ACT is pretty cosy with the FDA and I think that they will
allow a much more relaxed patient criteria for the AMD trails.

If GR though there was going to be a major delay in the AMD trails
he wouldn't be asking for a R/S at this time. Even with Camofi
issues.

[Med.rare]

I'm not selling either and keep buying with the price down here increasing my share count.